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Abstract
Background: The absence of antibodies specific for the 19 kDa C-terminal domain of merozoite surface protein 1
(MSP119) has been associated with high-density malaria parasitaemia in African populations. The hypothesis that a
high prevalence and/or level of anti-MSP119 antibodies that may inhibit erythrocyte invasion would be present in
apparently healthy individuals who harbour a sub-microscopic malaria infection was tested in this study.
Methods: Plasma samples were collected from residents in a region in Nigeria hyperendemic for malaria, who had
no detectable parasitaemia by microscopy. Using a competition-based enzyme-linked-immunosorbent assay with
two invasion-inhibitory monoclonal antibodies (mAbs) 12.10 and 12.8, the levels and prevalence of specific
antibodies were measured. The minimum multiplicity of infection was determined using PCR. The prevalence of
anaemia was also measured.
Results: Plasma samples from 85% of individuals contained antibodies that bound to MSP119. The inhibition of mAb
12.10 binding was strongly correlated with the prevalence (Spearman correlation test, p < 0.0001) and mean titre of
anti-MSP119 antibodies (Spearman correlation test, p < 0.001) in the samples. Comparing samples from individuals
with multiple infection (group M) and single infection (Group S), group M contained a higher (p = 0.04) prevalence
of anti-MSP119 antibodies that competed with mAb 12.10. Using a logistic regression model, it was found that the
presence of antibodies competitive with mAb 12.10 was affected negatively by anaemia (p = 0.0016) and positively
by the carriage of multiple parasite genotypes (p = 0.04).
Conclusions: In the search for correlates of protection against malaria, which will be essential to evaluate clinical
trials of malaria vaccines based on MSP1, this study examines some potential assays and the factors that need to
taken into account during their evaluation, using samples from individuals naturally exposed to malaria infection.
Background
Among many Plasmodium falciparum merozoite surface
antigens, merozoite surface protein (MSP) 1 has been
shown to be one of the major targets of antibodies that
inhibit the invasion of red blood cells [1-3]. The protein
is present on the merozoite surface as a complex of
polypeptides that includes a glycosylphosphatidyl inosi-
tol (GPI)-anchored 42 kDa C-terminal fragment
(MSP142). During merozoite invasion into the red blood
cell MSP142 is processed to yield 33- and 19-kDa frag-
ments (MSP133 and MSP119, respectively). Only the GPI
anchored MSP119 remains on the merozoite during ery-
throcytes invasion [4,5]. Some mouse monoclonal anti-
bodies (mAbs) including 12.8 and 12.10 [6] that inhibit
the invasion of red blood cells also inhibit the
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processing of MSP142 [7]. However, it is still not clear
that this activity is a significant contribution to protective
immunity acquired following exposure to the parasite [8].
Several immuno-epidemiological studies have yielded
conflicting results with regards to the association
between anti-MSP119 antibodies and protection against
clinical malaria [9-15]. At least one study [16] has indi-
cated that the total anti-MSP119 antibody titre is a poor
indicator of malaria immunity, suggesting that antibody
fine specificity is very important. It has been proposed
that functional assays such as growth inhibition assays
[17], inhibition of MSP142 processing [2] or Fc-mediated
effector mechanisms [18] may provide a more informa-
tive readout to identify useful antibodies. The fine speci-
ficity of such functional antibodies may be examined
using a numbers of methods including direct binding to
antigen or modified antigen [19,20] or competition
assays using defined mAbs [21-23]. Using these
approaches different classes of antibody have been
defined and their epitopes partially mapped; for example
MSP142 processing and merozoite invasion inhibitory
antibodies, blocking antibodies that block the activity of
invasion inhibitory antibodies, and neutral antibodies
that have no effect on MSP142 processing and merozoite
invasion [2,8,20,24].
MSP119-specific invasion inhibitory activity has been
associated with resistance to reinfection in Kenya [25].
However, parasite inhibitory activity is limited to a small
subset of total anti-MSP119 antibodies. mAbs 12.8 and
12.10 have been used in several sero-epidemiological
studies [16,21,23]. In one study in The Gambia [21],
individuals with anti-MSP119 antibodies that compete
with mAb 12.10 in a specific ELISA, were significantly
less likely to have malaria infections with densities of ≥
1,000 parasites/μl. In a study in Uganda, competition
with mAb 12.10 was highly correlated with resistance to
high-density parasitaemia, but there was no such asso-
ciation with mAb 12.8 [23]. The precise epitope map-
ping of both mAbs has been reported recently [26,27]
and although there is considerable overlap of the two
epitopes the data above suggest different functions for
the corresponding antibodies [26].
A previous study carried out in the rural area of Igbo-
Ora, South-western Nigeria [16] showed no correlation
between the level of naturally acquired anti-MSP119
antibodies and inhibition of MSP142 processing in
plasma samples from P. falciparum infected children
and adults. To test the hypothesis that in apparently
healthy individuals who harbour sub-microscopic
malaria parasite infections there would be a high preva-
lence and/or high level of anti-MSP119 antibodies that
compete with mAbs 12.8 and 12.10, further investiga-
tions in the Igbo-Ora population were carried out. To
test this hypothesis, apparently healthy subjects without
detectable parasites by thick and thin blood smears
within all age groups were recruited and both the total
antibody response to recombinant MSP119 and the fine
specificity of anti-MSP119 antibodies using a competitive
ELISA with mAbs 12.8 and 12.10 were assessed. In a
second objective, an effect of multiplicity of infection
was examined. As carriage of multiple P. falciparum
clones can be a useful indicator of the immune status of
the host [28,29], the relationship between this parameter
and the level of antibodies competing with the mAbs
has also been investigated. Finally, the third objective of
this work was to determine whether or not there was
any association between the presence of specific inva-
sion inhibitory antibodies, the anaemia status of the sub-




The cross-sectional study was conducted in Igbo-Ora, a
rural area in south-western Nigeria; approximately 100
km from the state capital Ibadan. In Igbo-Ora malaria is
hyperendemic with a prevalence of approximately 75%
in children during the raining season from April to
October and 55% to 60% during the dry season from
November to March. The peak incidence was observed
in November and August, with lower rates observed in
July, September and October [30].
Subjects and blood collection
Enrollment was carried out in September and October
2000. Asymptomatic carriers of a P. falciparum infection
were defined as individuals with detectable blood stage
parasites and an axilliary temperature <37.5°C, who had
not received any anti-malarial drug in the preceding fif-
teen days and who did not present any malaria symp-
toms for at least seven days following blood sampling.
Children homozygous for the sickle cell trait (HbSS) as
well as children with HbSC were excluded from the
study. The protocol was explained to the assembled vil-
lage population and informed consent was obtained
individually from each participant or his/her parents;
the study was approved by the Ethical Committee of
University College Hospital, Ibadan, Nigeria.
Blood was collected by venipuncture into heparinized
and EDTA containing tubes. Thick and thin blood
smears were stained with Giemsa for microscopic detec-
tion of malaria parasites, examining 200 fields. Malaria
parasites were counted relative to leukocytes, and a leu-
kocyte count of 8,000/μl of blood was assumed. Blood
slides were examined using the quality control proce-
dures described elsewhere [30]. Red blood cells were
separated from the plasma by centrifugation and both
were stored at -80°C prior to further analysis.
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Haemoglobin type was determined by electrophoresis
on cellulose acetate gel with alkaline buffer. Packed cell
volume (PCV) was determined using a haematocrit cen-
trifuge (Hawksley and Sons, Ltd., Lancing, United King-
dom). Anaemia was defined according to the age-
dependent PCV levels published by the WHO (0-3
months: < 32%, 6 months-4 years: < 33%, 5-11 years:
<34%, >12 years: < 37%; for adults, male: < 40% and
female: <37%).
Genotyping of P. falciparum msp1
DNA was extracted from blood cells using the QIAamp
DNA blood mini kit (Qiagen) according to the manufac-
turer’s procedure. Single and nested PCRs were per-
formed to amplify the polymorphic sequence block 2 of
P. falciparum msp1 as described previously [31]. Amplifi-
cations were performed in a final volume of 50 μl and
cloned or monomorphic parasite lines were used as posi-
tive template controls. The first round PCR amplification
was performed using two microlitres of DNA and the pri-
mers 5′-AAGCTTTAGAAGATGCAGTATTGAC-3′ and
5′-ATTCATTAATTTCTTCATATCCATC-3′, designed
on the conserved regions in sequence blocks 1 and 3 on
either side of block 2. The second round nested PCR
amplification was carried out using 2 μl of the primary
amplified products. Primers were used for detecting the





5′-GAACAAGTCGAACAGCTGTTA-3′) msp1 block 2
sequence families [32]. The amplifications were per-
formed in a Biometra Uno II thermal cycler (Biometra,
Göttingen, Germany) and the products were loaded onto
a 1.5% agarose gel (Peqlab Erlagen, Germany), electro-
phoresed and stained with ethidium bromide. The DNA
was visualised under ultraviolet light and the fragment
size polymorphism for each allelic family was deter-
mined. It was assumed that each PCR fragment repre-
sented at least one parasite genotype.
MSP119 recombinant protein
The recombinant PfMSP119 protein (rMSP119) was
prepared by standard techniques as a glutathione S-
transferase (GST) fusion protein by expression from a
pGEX-3X plasmid as described previously [33] and it
represents the sequence of the Wellcome parasite line
[34] (EMBL accession number X02919).
Enzyme-linked immunosorbent assay (ELISA)
An indirect ELISA was performed to determine the pre-
valence and titre of IgG antibodies binding to rMSP119,
as previously described [16]. Ninety six well-polystyrene
microtitre plates (Costar, Corning Inc. NY) were coated
with 0.5 μg/ml rMSP119. Following incubation with
diluted plasma samples, bound antibodies were detected
with horseradish peroxidase (HRP)-rabbit anti-human
IgG conjugate (Dako, Denmark) and ABTS/hydrogen
peroxidase substrate solution by measuring the absor-
bance at 650 nm. The plasma samples were diluted at a
1:25 ratio and then in two fold dilutions to 1:3200; the
reciprocal end point titre (the highest dilution that gave
an absorbance value greater than the background level
measured with negative control samples) was log trans-
formed, and data were expressed as geometric mean log
reciprocal titres. The negative control samples were
obtained from malaria-naïve residents of the United
Kingdom.
Competition ELISA assays
The ability of polyclonal antibodies in the human
plasma samples to compete with mAbs 12.8 and 12.10
for binding to rMSP119 was examined by competitive
ELISA [22]. Initially each mAb was titrated against the
rMSP119 and then used in the competition assay at a
concentration that gave an absorbance reading just
below the maximal absorbance for that antibody (i.e.
just below the top of the titration curve). Microplate
wells were coated with 0.1 μg of rMSP119, then plasma
at a dilution of 1:50 or 1:250 was added to duplicate
wells, and the plates were incubated overnight at 4°C. A
predetermined amount of mAb was then added and
incubation continued overnight; the amount of bound
mAb was determined as described previously [22].
Plasma samples were divided into two groups: non-com-
petitive samples, which were those that inhibited the
mAb binding by less than 50% at a 1:250 dilution and
competitive samples, which were those that inhibited
the mAb binding by more than 50% at a 1:250 dilution.
Statistical analysis
The multiplicity of infection (mean minimum number of
different parasite genotypes per infected subject) was
estimated by dividing the total number of msp1 PCR
fragments representing different genotypes by the num-
ber of infected subjects. Infection was categorized as a
nominal variable as follows: M (multiple, ≥ 2 parasite
genotypes), S (single, 1 parasite genotype). The non-
parametric Kruskall-Wallis and Mann-Whitney U tests
were used to compare continuous variables between
three (or more) and two groups, respectively. The chi
square test was used to compare nominal data. The
antibody response was divided into two groups: high
competition/low mAb binding (≥50% inhibition of bind-
ing) and low competition/high mAb binding (<50% inhi-
bition of binding). The effect of various parameters on a
high or low competitive binding for both mAb 12.8 and
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12.10 was evaluated by logistic regression. Statistical
analysis of data was performed using the JMP 5 statisti-
cal software. Differences were considered statistically
significant at a p value of less than 0.05.
Results
Characteristics of subjects
During the enrolment period, of 147 subjects recruited
who had no detectable parasites by microscopy on
Giemsa-stained thick and thin blood smears and who
met the inclusion criteria, 143 had P. falciparum infec-
tions detectable by PCR with msp1-specific primers.
Some characteristics of these subjects including sex,
haemoglobin type, mean PCV and their use of bed and/
or window nets are given in Table 1. Fifty nine percent
of recruited individuals were found to be anaemic, parti-
cularly amongst younger subjects: 63% of less than 1
year-olds, 33% of 1 to 5 year-olds and 17% of 6 to 15
year-olds had PCVs below the WHO threshold, respec-
tively. This decrease in anaemia with age was significant
(p < 0.0001, r = 0.56).
Prevalence of IgG antibodies reacting with rMSP119
protein
Antibodies reacting with rMSP119 were detected in 85%
of the individuals with sub-microscopic infections.
There was a significant increase in the proportion of
responders to rMSP119 protein (p < 0.0001) and in the
mean log titre of anti-MSP119 antibodies (Spearman
correlation, p < 0.0001) with age, as shown in Table 2.
Human antibodies that compete with mAbs 12.10 and
12.8 for binding to rMSP119
There was marked heterogeneity in the ability of poly-
clonal antibodies to compete with the MSP119-specific
mAbs. The samples were divided into two groups: those
containing highly competitive antibodies resulting in low
binding of mAb to rMSP119 (≥ 50% inhibition of bind-
ing), and those containing poorly competitive antibodies
resulting in high binding of mAb to rMSP119 (<50%
inhibition of binding). As shown in Table 2, 39% (57 of
147) of samples contained antibodies that were highly
competitive to mAb 12.10 binding to rMSP119. The 1-
to 5 year-old age group contained the lowest prevalence
of antibodies competitive with mAb 12.10 and although
the inhibition of mAb 12.10 binding varied between age
groups the difference was not significant. The inhibition
of mAb 12.10 binding correlated strongly with the pre-
valence of total anti-MSP119 antibodies (Spearman cor-
relation test, p < 0.0001) and with the mean titre of
anti-MSP119 antibodies (Spearman correlation test, p <
0.001) (Table 3). Forty-six of the 147 samples (31%)
contained antibodies that competed with mAb 12.8, and
there was a correlation between the presence of such
antibodies and age (p < 0.001). There was also a strong
correlation of competition with mAb 12.8 and the pre-
valence and mean titre of polyclonal anti-MSP119 anti-
bodies (p < 0.0001) (Tables 2 and 3). Overall, plasma
samples containing antibodies highly competitive with
both mAbs were also those with the highest titres of
total anti-MSP119 antibodies (Table 3).
Table 1 Characteristics of the subjects with P. falciparum sub-microscopic infections in Igbo-Ora village, Nigeria
Factor Number of subjects aSex (F/M) bNets (%) cPCV dP
Age (years)
<1 38 20/18 32 (84) 31.7 (6.8) <0.0001
1 - 5 24 16/8 24 (100) 33.4 (2.7) -
6 - 15 36 20/16 26 (72) 37.0 (3.7) -
>15 49 37/12 38 (77) 39.5 (4.5) -
Haemoglobin phenotype
AA 135 85/50 111 (82) 34.7 (5.7) ref
AS 11 7/4 8 (73) 38.2(4.7) 0.14
AC 1 1/0 1 (100) 30 nd
eMinimum number of MSP1 genotypes
0 to 1* 74 48/26 62 (84) 34.6 (5.3) 0.86
2 to 3 68 41/27 54 (79) 35.0 (6.1) -
4 to 5 5 4/1 4 (80) 35.8 (2.3) -
Total 147 93/54 120 (82) 34.8 (5.6)
a Sex: F, female; M, male.
b Nets: indicates the use of bed and/or window nets; actual numbers and proportion of subjects (%).
c PCV: mean packed cell volume (SD).
d P value for differences in PCV; nd: not done.
e Number of MSP1 genotypes was determined by PCR, the presence of 1 or more indicates the presence of parasites.
*Four samples did not produce a PCR product with the MSP1 primers.
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Genetic diversity in msp1 sequence block 2 and
multiplicity of infection
It was of interest to determine whether or not multipli-
city of infection (MOI), and the numbers of different
MSP1 types affected either the total amount of MSP119-
specific antibody or of antibody that competed with the
mAbs, and therefore the number of msp1 sequence
block 2 types in the samples was used as a marker for
MOI and MSP1 polymorphism in each individual. Gen-
otyping of the polymorphic sequence block 2 revealed
that RO33 was the predominant allele with 57% of the
total, with the K1 and MAD20 allelic families represent-
ing 26% and 17%, respectively. Based on size poly-
morphism, only one RO33 allele was detected whereas
the MAD20 and K1 families contained 8 and 13 distinct
alleles, respectively (Figure 1). There was no preferential
distribution of allelic families between age-groups. The
mean minimum MOI based on the number of msp1
genotypes detected for individuals in each age-group is
shown in Table 2. The highest MOI was found in the 6
to 15 years age group. Seventy-three of 147 (51%) iso-
lates were found to have more than one P. falciparum
genotype. There was no significant influence of age on
the proportion of individuals with multiple versus single
infections (denoted by M and S, respectively in Table 2)
or on MOI. Overall, no correlation between MOI and
the mean log titre of anti-MSP119 antibodies was
detected. Similarly the MOI was not correlated with
inhibition of mAb 12.10 binding. However, comparing
the two groups M (multiple infection) and S (single
infection), there was a higher prevalence of antibodies
that competed with mAb 12.10 in samples from group
M (Table 3, p = 0.04).
Relationship between MOI, anaemia, and the inhibition of
mAb binding
The proportion of individuals with anaemia decreased
with age (Figure 2). Using logistic regression, the asso-
ciation of anaemia and the carriage of multiple P. falci-
parum genotypes on the total MSP119-specific antibody
Table 2 Relationship between subjects’ age, titre of anti-MSP1 antibodies, inhibition of binding of specific monoclonal
antibodies and multiplicity of infection
Age (years) Total Number of Subjects aAntibodies to rMSP1 bmAb12.10 mAb12.8 cInfection
Responders (%) Mean Log titre H (%) H (%) M S MOI
<1 38 23 (61) 2.21 7 (18) 8 (21) 14 23 1.5
1 - 5 24 20 (83) 2.35 2 (8) 7 (29) 12 11 1.8
6 - 15 36 34 (94) 2.69 33 (92) 13 (36) 27 8 2.2
>15 49 48 (98) 2.94 15 (31) 18 (37) 20 28 1.5
Total 147 125 (85) 2.60 57 (39) 46 (31) 73 70 1.7
aAntibodies to rMSP1: Responders is the number of subjects with antibodies against recombinant MSP1,(%) is the percentage of the total.
bmAb12.10 and mAb 12.8: H refers to the number of individuals with antibodies highly competitive with the mAb; (%) is the percentage of the total.
cInfection: M refers to individuals with two or more parasite clones; S refers to individuals with only one parasite type detected. MOI is the mean multiplicity of
infection based on MSP1 block 2 alleles.
Table 3 The multiplicity of P. falciparum infection and mean titer of anti-MSP1 antibodies, in subjects with antibodies
that are either highly competitive (H) or poorly competitive (L) with the specific monoclonal antibodies
aMonoclonal antibody Number of subjects cInfection dAntibodies to rMSP1
Total n = 147 bInfected M S MOI Prevalence P Mean log titre P
12.8
Poorly competitive (L) 100 99 50 49 1.73 78% 0.0006 2.3 0.0001
Highly competitive (H) 46 43 22 21 1.65 100% 3.2
12.10
Poorly competitive (L) 90 87 38* 49 0.86 77% 0.002 2.4 0.0001
Highly competitive (H) 57 56 35 21 0.98 96% 2.9
12.8 and 12.10
Poorly competitive (L) 75 74 33 ** 41 1.62 73% 0.0007 2.3 0.0001
Highly competitive (H) 32 31 18 13 1.77 100% 3.2
aMonoclonal antibody. mAb12.10 and mAb 12.8: L and H refer to the number of individuals with antibodies that are either poorly competitive or highly
competitive with the monoclonal antibodies, respectively.
bInfected: number of subjects positive by PCR.
cInfection: M refers to individuals with two or more parasite clones, S refers to individuals with only one parasite type detected. MOI is the mean multiplicity of
infection based on MSP1 block 2 alleles.
dAntibodies to rMSP1: Prevalence is the number of subjects with antibodies against recombinant MSP1 as a percentage of the total.
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and the competitive activity with mAbs 12.10 and 12.8
were examined. Anaemia was significantly associated
with total anti-MSP119 antibody (p = 0.0016) with a low
prevalence of antibodies that competed with mAb 12.10;
whereas harbouring more than 1 parasite genotype
(group M) was associated (p = 0.04) with a greater pre-
valence of antibodies that competed with mAb 12.10.
This was not observed with MAb 12.8: the presence of
antibody competitive with mAb 12.8 was influenced
neither by the presence of multiple P. falciparum geno-
types nor by anaemia.
Discussion and Conclusions
The first candidate malaria vaccines based on MSP1 are
now being evaluated in clinical studies [35]. However, in
view of the disappointing results in the first MSP1
clinical trial in Kenya [36], there is an urgent need to
define useful correlates of protective immunity and sur-
rogate assays to evaluate malaria vaccines based on
MSP119 and other parts of the molecule.
The two mAbs 12.10 and 12.8, which inhibit the inva-
sion of red blood cells and have overlapping epitopes
[26], have been found to be useful in field studies to dis-
criminate the potential contribution of each specificity to
protection against clinical malaria or high-grade parasi-
taemia [21,23]. Asymptomatic carriage of parasites by
young children as well as adults [37] reflects their ability
to control the malaria infection through the presence of
effective innate or acquired immune mechanisms. There-
fore it was proposed that in the samples from such indi-
viduals, with a parasitaemia undetectable by microscopy,
that there would be antibodies which would be highly
effective at inhibiting parasite invasion of red blood cells,
as reflected by higher competition with the mAbs 12.8
and 12.10 for binding to MSP119. In addition, it was of
interest to evaluate whether or not there is an association
between the level of antibodies that inhibit red blood cell
invasion (assessed indirectly by the competition with the
mAbs) and the carriage of sub-microscopic infections
comprised of multiple parasite clones, and representing
an antigenically diverse parasite population.
In our Nigerian cohort, 85% of plasma samples con-
tained anti-MSP119 antibodies. Both the prevalence and
the mean titre of anti-MSP119 antibodies were signifi-
cantly correlated with the age of the donor. This finding
differs from that in a previous report from the same
area [16], which noted a decline in the MSP119-specific
antibody titre with age in samples collected in the rainy
season, whereas in samples collected in the dry season
higher antibody titres were observed for children of six
years of age or older than for younger children. In stu-
dies carried out in the Gambia and Uganda, the preva-
lence and mean anti-MSP119 antibody levels did not
increase with age [21,23]. This discrepancy between the
studies may be explained by differences in the intensity
of malaria transmission, in the time of sample collection
(seasonal variation) or in study design. Indeed, in the
Gambian and Ugandan studies, individuals were followed
up for some weeks and the objective was to search for
association between outcome of the infection and rein-
fection and high parasite load. In our cross-
sectional survey, parasitaemia was a controlled parameter.
In the competition ELISA, 39% and 31% of samples
contained antibodies that strongly inhibited the binding
of mAb 12.10 and mAb 12.8, respectively. The inhibi-
tion of mAb 12.8 binding correlated positively with the
titre of total anti-MSP119 antibodies as also found in
Uganda, but not in The Gambia [23]; no influence of
the age of the donor was found in these studies. Whilst
competition with mAb 12.10 also correlated positively
Figure 1 Distribution and prevalence of MSP1 alleles within
sequence block 2 that were identified in the cross sectional
survey. The different alleles fall into 3 different sequence families
(RO33, MAD20, and K1) within which there are size polymorphisms
identified by the size of the PCR amplified fragment (shown in base
pairs, bp).
Figure 2 Prevalence of individuals with antibodies reacting
with recombinant MSP1, with anaemia, with infection with two
or more parasite clones, and with multiplicity of infection
(MOI), for the different age-groups.
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with total anti-MSP119 antibody titres in the Nigerian
samples, there was no significant change in the preva-
lence of these competing antibodies with age as
observed in the other African sites [21,23].
The mAbs 12.8 and 12.10 are antibodies that inhibit
the secondary processing of MSP1 as well as the inva-
sion of red blood cells. Previously this functional anti-
body activity was detected in samples similar to those
we report on here [16] and this activity did not correlate
with the titre of total anti-MSP119 antibody. Although a
competition ELISA assay with mAbs 12.8 and 12.10
might be expected to provide a surrogate read-out for
this function the situation is complicated by the poten-
tial presence of so-called blocking antibodies that com-
pete with 12.8 and 12.10, but do not themselves inhibit
MSP1 processing or erythrocyte invasion [24].
In malaria endemic regions, anaemia has multiple
causes e.g. polyparasitism, poor nutrition or immune
depression. It can also result from both acute and
chronic malaria [38]. A high MOI is considered to
reflect acquired immunity or premunition [39] and to
reduce the risk of clinical malaria and morbidity [28,29],
in part by selection against virulent parasites. However,
May et al [40] showed that a high multiplicity of P. fal-
ciparum infection can be associated with an increased
risk of anaemia. Here, in infants and older children with
sub-microscopic infection, no association was found
between MOI and anaemia status. However, the multi-
plicity of infection may have been underestimated [29]
because only one blood sample was collected per indivi-
dual and fluctuations in sequestered parasite populations
and the sensitivity of the PCR method [41] may limit
detection at low parasitaemia. In addition, the use of a
single genetic marker can only provide a minimum esti-
mate of diversity in the parasite population.
Immune responses (e.g. production of various cyto-
kines) that vary with different parasite strains may con-
tribute to the unequal impact of distinct parasite
genotypes on haemoglobin levels.
An evaluation of the association of non severe malarial
anaemia and P. falciparum polyclonal infections on the
prevalence of antibodies which compete with mAb
12.10 showed that anaemia and carriage of multiple
infections had a negative and a positive association,
respectively. This association was not found for the pre-
valence of antibodies competing with mAb 12.8 binding.
Interestingly, the possession of anti-MSP119 antibodies
that compete with mAb 12.10 and not 12.8 has been
associated with resistance to high-density parasitaemia
[21,23]. These observations support not only the pro-
posed importance of antibody fine specificity in playing
a major role in protection against parasite load but also
suggest a differential contribution of the overlapping
specificities identified so far.
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